Prenatal Genetic Testing Insurance Denied? How to Appeal NIPT and cfDNA Coverage

Prenatal genetic testing has transformed obstetric care. Non-invasive prenatal testing (NIPT), also called cell-free DNA (cfDNA) screening, analyzes fetal DNA circulating in maternal blood to screen for chromosomal abnormalities — trisomy 21 (Down syndrome), trisomy 18, trisomy 13, and sex chromosome aneuploidies — with high sensitivity and low false-positive rates. Despite its clinical value, insurers frequently deny cfDNA/NIPT, particularly for patients classified as "average risk." Understanding the coverage landscape and how to challenge these denials can make a significant financial difference.

The Coverage Divide: High-Risk vs. Average-Risk Pregnancies

Until recently, most insurers covered NIPT only for "high-risk" pregnancies — those with advanced maternal age (typically defined as age 35 or older at delivery, or AMA), abnormal first-trimester serum screening results, prior affected pregnancy, or identified fetal anomaly on ultrasound. For these patients, coverage is well-established and denials are directly appealable.

For average-risk pregnancies (patients under 35 with no additional risk factors), coverage has historically been denied, with insurers citing standard serum screening (quad screen, first-trimester combined screening) as sufficient. However, this landscape has shifted. In 2022, ACOG and the Society for Maternal-Fetal Medicine (SMFM) updated their guidelines to state that cfDNA screening should be available to all pregnant patients, not just high-risk, and that it is the most sensitive screening test for common trisomies.

Following these guideline updates, many insurers began expanding coverage. If your plan has not updated its coverage criteria to reflect current ACOG/SMFM guidance, this is grounds for a medical necessity appeal.

Understanding the Screening vs. Diagnostic Distinction

This is one of the most common sources of coverage confusion in prenatal genetic testing. Insurers often cover screening differently from diagnostic testing:

Screening (NIPT/cfDNA, quad screen, first-trimester combined screen) identifies patients at elevated risk for chromosomal abnormalities. A positive or high-risk screening result does not confirm a diagnosis.

Diagnostic testing (chorionic villus sampling [CVS] or amniocentesis) definitively diagnoses chromosomal conditions. These carry a small procedure-related risk of pregnancy loss.

When a screening test (NIPT) is denied and the insurer covers amniocentesis instead, they may be claiming that the less-invasive option is not cost-effective. This is a perverse incentive: the insurer is declining to cover a blood test and offering a procedure with miscarriage risk as the alternative. Appeals that highlight this absurdity — citing ACOG guidance that NIPT reduces the need for invasive testing — are compelling.

ACA Preventive Services and Prenatal Testing

Under the ACA, plans must cover USPSTF Grade A and B preventive services without cost-sharing. As of 2023, the USPSTF recommends screening for certain chromosomal conditions in pregnant women. If NIPT constitutes a preventive screening service under applicable USPSTF recommendations, it may be covered without a copay or deductible under your plan's preventive care benefit.

Check your plan's preventive care schedule and the USPSTF website for current recommendation grades relevant to prenatal screening. If the test was billed as a diagnostic service but qualifies as preventive screening, rebilling under the correct category may resolve the denial.

Common Denial Reasons and How to Counter Them

"Patient does not meet age or risk criteria." Counter with updated ACOG/SMFM 2022 guidelines stating cfDNA is appropriate for all pregnant patients. Submit the full guideline text with your appeal letter.

"Serum screening is adequate." Counter with published data showing cfDNA's superior sensitivity and specificity compared to quad screen, and the reduction in false positives that lead to unnecessary amniocentesis.

"Test performed by out-of-network lab." This is a billing dispute rather than a medical necessity denial. Many NIPT labs (Natera, Labcorp, Quest, Sequenom) are not in every insurer's network. If the ordering physician is in-network and the lab was not disclosed as out-of-network at the time of ordering, No Surprises Act protections may apply.

"Experimental or investigational." This denial reason is difficult to sustain given the decade of published evidence supporting cfDNA. Cite ACOG Practice Bulletin No. 226 and the SMFM Consult Series on cell-free DNA screening.

When Your Provider Ordered Both Serum and cfDNA

Some providers order both first-trimester serum screening and NIPT in the same pregnancy. Insurers may deny one as duplicative. The ordering physician should document why both tests were ordered — for example, serum screening provides additional information (nuchal translucency ultrasound, maternal serum analytes) that cfDNA does not, and the combination may be clinically indicated.

Fight Back With ClaimBack

ClaimBack helps expectant parents fight back against prenatal testing denials. Our platform generates appeals citing the most current ACOG, SMFM, and USPSTF guidance, matched to your specific denial reason.

Start your prenatal testing appeal now

Related Reading

• What Is Medical Necessity?
• How to Write an Insurance Appeal Letter
• Common Reasons Insurance Claims Are Denied